The Japan-based pharmaceuticals company transfers an irritable bowel syndrome drug to Drais and invests $13m with venture firms, in a similar deal to one hatched by Astellas two months ago.
Astellas Pharma, a Japan-based pharmaceuticals company, has transferred a second drug to the management of US-based Drais Pharmaceuticals after it hatched a similar deal in April.
Astellas will transfer ownership of ASP7147, which treat irritable bowel syndrome with diarrhea, to Seldar Pharma, a virtual company operated by Drais.
In April Astellas and Drais hatched a similar deal, creating Telsar, to operate another drug, ASP3291.
Seldar and Telsar are both backed by the same investors, Astellas’ corporate venturing unit Astellas…
